All In Biotech

Drug Trial Radar · NCT06859775

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Open-label, Multicenter Phase Ib/II Clinical Study of Injectable SHR-A1811 in Combination Regimens for the Treatment of Recurrent or Metastatic Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 25, 2025

Primary completion

Oct 2026

Study completion Jan 2027

Sponsor

Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.

Conditions

  • Recurrent or Metastatic Cervical Cancer

Interventions

  • SHR-A1811Drug

    SHR-A1811 injection.

  • Adebelimab injectionDrug

    Adebelimab injection.

  • Bevacizumab injectionDrug

    Bevacizumab injection.

  • SHR-8068Drug

    SHR-8068 injection.

  • Cisplatin injectionDrug

    Cisplatin injection.

  • Carboplatin injectionDrug

    Carboplatin injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Grade≥3 drug-related adverse events (TRAEs).Time frame: Up to 3 years.
  2. Grade≥3 drug-related serious adverse events (TRAEs).Time frame: Up to 3 years.
  3. Objective response rate (ORR).Time frame: Up to 3 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.